27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- On Tuesday, analysts at Morgan Stanley took a look at AstraZeneca plc (ADR) (NYSE: AZN) as it starts to reap the benefits of the strategic changes that CEO Soriot implemented three years ago.
- After a double upgrade, the firm rates the stock an Overweight, setting a 53 Pounds price target for London-traded AstraZeneca plc (LON:AZN) shares.
- The experts see several pipeline catalysts for the year to come, and believe “a floor EPS of $4.20 looks plausible.”
After years of substantial investments, AstraZeneca seems to offer “good pipeline optionality and more reasonable expectations,” analysts at Morgan Stanley noted in a recent report. The experts see upside risk to consensus for fiscal 2016 and fiscal 2017, as the estimates ignore “AstraZeneca levers to reach its floor $4.20 core EPS despite patent expiries (growth platforms/launches on existing infrastructure with material savings, externalization revenue).”
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The firm consequently launched its 3-year CAGR earnings estimate to 2019, which “captures the profitability inflexion point and allows for 10%+ growth.” Based on these projections, the experts decided to upgrade the stock from Underweight to Overweight, boosting their price target by 10 Pounds, to 53 Pounds.
The report highlighted a few major R&D catalysts coming up in 2016. The company’s renewed focus on R&D should finally pay out in 2016, as Phase 3 readouts for three main assets and three new launches take place. The firm estimates up to $9 billion combined opportunity – or 6 Pounds per share NPV from assets outside of the immune-oncology field.
Moreover, the news flow for immune-oncology assets will see a significant acceleration as of the end of 2016, with multiple notable readouts coming up.
Finally, the experts looked into valuation. Apparently, AstraZeneca trades at a 10 percent P/E discount to its peers. And, according to the analysts, this valuation does not reflect the company’s long-term growth potential.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.